Using the BRAVO Risk Engine to Predict Cardiovascular Outcomes in Clinical Trials With Sodium–Glucose Transporter 2 Inhibitors | Zendy

Hui Shao | Zendy; Lizheng Shi | Zendy; Vivian Fonseca | Zendy

Open Access

Using the BRAVO Risk Engine to Predict Cardiovascular Outcomes in Clinical Trials With Sodium–Glucose Transporter 2 Inhibitors

Author(s) -

Hui Shao,

Lizheng Shi,

Vivian Fonseca

Publication year - 2020

Publication title -

diabetes care

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 6.636

H-Index - 363

eISSN - 1935-5548

pISSN - 0149-5992

DOI - 10.2337/dc20-0227

Subject(s) - empagliflozin , medicine , dapagliflozin , canagliflozin , myocardial infarction , diabetes mellitus , timi , blood pressure , type 2 diabetes , clinical trial , hazard ratio , stroke (engine) , unstable angina , angina , thrombolysis , confidence interval , endocrinology , mechanical engineering , engineering

This study evaluated the ability of the Building, Relating, Assessing, and Validating Outcomes (BRAVO) risk engine to accurately project cardiovascular outcomes in three major clinical trials-BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME), Canagliflozin Cardiovascular Assessment Study (CANVAS), and Dapagliflozin Effect on Cardiovascular Events-Thrombolysis in Myocardial Infarction (DECLARE-TIMI 58) trial-on sodium-glucose cotransporter 2 inhibitors (SGLT2is) to treat patients with type 2 diabetes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research